Glucose and Insulin Response in Adults with Type 2 Diabetes

Société des Produits Nestlé (SPN)1 site in 1 country16 target enrollmentAugust 2, 2021

ConditionsDiabetes Mellitus, Type 2

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Diabetes Mellitus, Type 2
Sponsor: Société des Produits Nestlé (SPN)
Enrollment: 16
Locations: 1
Primary Endpoint: Post-prandial glycemic markers
Status: Completed
Last Updated: last year

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This will be a randomized crossover design with oral nutrition supplement interventions.

Detailed Description

This will be a randomized crossover design with two oral nutrition supplement interventions. The subjects will be randomized to one of two interventions on two separate study days, one week apart.

Registry

clinicaltrials.gov

Start Date

August 2, 2021

End Date

October 5, 2021

Last Updated

last year

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Société des Produits Nestlé (SPN)

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Age 20-75 years
•Type 2 diabetes controlled with diet or diet and metformin (Glucophage)
•Hemoglobin A1C less than 9.0%
•Fasting blood glucose less than 180 mg/dl
•Hematocrit levels within normal limits
•Having obtained his/her informed consent

Exclusion Criteria

•Abnormal thyroid function
•Creatinine \>2.0 mg/dl
•Potassium \<3.5 mEq/l
•Gastrointestinal disease: ulcer, gastritis, diarrhea, gastroparesis, vomiting
•Currently unstable diabetes or under treatment for cancer, heart disease, renal disease
•Patients with anemia
•Current insulin therapy or insulin therapy within the past month
•Patient who are pregnant
•Allergies to milk, soy or any component of the test product
•Patient who in the investigators assessment cannot be expected to comply with treatment

Outcomes

Primary Outcomes

Post-prandial glycemic markers

Time Frame: [Time Frame: Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes]

Area under the blood glucose curve (AUC 0-240 minutes)

Secondary Outcomes

Post-prandial insulin markers([Time Frame: Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes])
Insulinogenic index([Time Frame: Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes])